- Bragar Eagel & Squire, P.C. is investigating BioVie Inc. (BIVI) for potential claims against its board of directors regarding **breach of fiduciary duties**.  **[1580149_7bdda772b8fb4b6ab72c2e2f4a2600d3_0]** 
- This investigation follows a class action complaint filed on **January 19, 2024**, covering a Class Period from **August 5, 2021, to November 29, 2023**.  **[1580149_7bdda772b8fb4b6ab72c2e2f4a2600d3_0]** 
- The claims stem from BioVie's **November 29, 2023**, disclosure of top-line data from its NE3107 clinical trial, which revealed **significant protocol deviations and Good Clinical Practice (GCP) violations at 15 sites**.  **[1580149_7bdda772b8fb4b6ab72c2e2f4a2600d3_1]** 
- Due to patient exclusions, the Phase 3 clinical trial **did not achieve statistical significance**, leading to a **more than 60% drop** in BioVie's share price to **$1.96 per share** on November 29, 2023.  **[1580149_7bdda772b8fb4b6ab72c2e2f4a2600d3_1]**

BioVie under investigation by Bragar Eagel & Squire, P.C.

- BioVi anticipates full enrollment for its Phase II Parkinson's trial by the **end of 2025**, with top-line data expected in **April or May 2026**.  **[0001580149_2173372_1]** **[0001580149_2173372_4]** 
- The company's Phase II Long COVID trial is enrolling well, with data readout projected for **mid-2026**, backed by a **$13 million grant**.  **[0001580149_2173372_1]** **[0001580149_2173372_5]** 
- BioVi submitted its Phase III protocol for the ascites clinical trial to the FDA three weeks prior to October 8, 2025, expecting a response by the **end of next week**.  **[0001580149_2173372_1]** **[0001580149_2173372_6]** 
- BioVi maintains a significant cash runway, extending to **2026**, which covers the expected data readouts for its Parkinson's and Long COVID trials.  **[0001580149_2173372_1]** 
- The estimated annual market potential for BioVi's ascites drug (BIV201) in the U.S. is between **$1.6 billion and $2 billion**.  **[0001580149_2173372_6]** **[0001580149_2173372_7]**

BIOVIE (BIVI)